12 April 2018 in Clinical Cancer Research
Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). Therefore, we have developed an affibody-based PET radioconjugate that quantitatively assesses HER3 changes induced by Hsp90 inhibition in vivo. Experimental Design: ZHER3:8698 affibody molecules were conjugated via the C-terminus cysteine to DFO-maleimide for 89Zr radiolabeling. The probe was characterized in vitro and in vivo in a panel of human breast cell lines and xenograft models with varying HER3 receptor levels. In addition, the radioconjugate was investigated as a tool to monitor the outcome of AUY922, an Hsp90 inhibitor, in an MCF-7 xenograft model. Results: We demonstrated that 89Zr-DFO-ZHER3:8698 can track changes in receptor expression in HER3-positive xenograft models and monitor the outcome of AUY922 treatment. Our in vitro findings showed that MCF-7 cells, which are phenotypically different from BT474, develop resistance to treatment with AUY922 through HER3/IGF-1Rβ–mediated signaling. Of note, the lack of response in vitro due to HER3 recovery was confirmed in vivo using 89Zr-DFO-ZHER3:8698–based imaging. Upon AUY922 treatment, higher radioconjugate uptake was detected in treated MCF-7 xenografts, correlating with an AUY922-induced HER3 upregulation concomitant with an increase in IGF-1Rβ expression. Conclusions: These data underline the potential of HER3-based PET imaging to noninvasively provide information about HER3 expression and to identify patients not responding to targeted therapies due to HER3 recovery. Clin Cancer Res; 24(8); 1853–65. ©2018 AACR.
20 February 2024 in Biomedical Physics & Engineering Express
COChristopher O’cAllaghan
A performance evaluation was conducted on the new General Electric (GE) digital Omni Legend PET-CT system with 32 cm extended field of view. The first commercially available clinical digital bismuth germanate system. The system does not use time of flight (ToF). Testing was performed in accordance with the NEMA NU2–2018 standard. A comparison was made between two other commercial GE scanners with extended fields of view; the Discovery MI − 6 ring (ToF enabled) and the Discovery IQ (non-ToF). A genetic evolutionary algorithm was developed to optimize image reconstruction parameters from image quality assessments. The Omni demonstrated average spatial resolutions at 1 cm radial offset as 3.9 mm FWHM. The total system sensitivity at the center was 44.36 cps/kBq. The peak NECR was measured as 501 kcps at 17.8 kBq ml−1 with a 35.48% scatter fraction. The maximum count-rate error below NECR peak was 5.5%. Using standard iterative reconstructions, sphere contrast recovery coefficients were from 52.7 ± 3.2% (10 mm) to 92.5 ± 2.4% (37 mm). The PET-CT co-registration accuracy was 2.4 mm. In place of ToF, the Omni employs software corrections through a pre-trained neural network (PDL) (trained on non-ToF to ToF) that takes Bayesian penalized likelihood reconstruction (Q.Clear) images as input. The optimum parameters for image reconstruction, determined using the genetic algorithm were a Q.Clear parameter, β, of 350 and a ‘medium’ PDL setting. Using standard iterative reconstructions, the Omni initially showed increased background variability compared to the Discovery MI. With optimized PDL reconstruction parameters selected using the genetic algorithm the performance of the Omni surpassed that of the Discovery MI on all NEMA tests. The genetic algorithm’s demonstrated ability to enhance image quality in PET-CT imaging underscores the importance of algorithm driven optimization and underscores the requirement to validate its use in the clinical setting.
2 November 2018 in IEEE Transactions on Radiation and Plasma Medical Sciences
ARAshrani Aizzudin Abd Rahni
Ashrani Aizzudin Abd Rahni
Respiratory motion degrades quantitative and qualitative analysis of medical images. Estimation and hence correction of motion commonly uses static correspondence models between an external surrogate signal and internal motion. This work presents a patient specific respiratory motion model with the ability to adapt in the presence of irregular motion via a Kalman filter with Expectation Maximisation for parameter estimation. The adaptive approach introduces generalizability allowing the model to account for a broader variety of motion. This may be required in the presence of irregular breathing and with different sensors monitoring the external surrogate signal. The motion model framework utilizing an adaptive Kalman filter approach is tested on dynamic MRI data of nine volunteers and compared to a state-of-the-art static total least squares approach. Results demonstrate the framework is capable of reducing motion to the order of < 3mm and is significantly (p<0.001) more effective in the presence of irregular motion, assessed using the F test for model comparison. Utilizing the total sum of squares of estimated vector field error from the calculated ground truth, we observe approximately a fifty percent reduction in root mean square error and thirty percent reduction in standard deviation utilizing the Kalman model (EKF) in comparison to a static counterpart.